Bausch & Lomb Corp key statistics and ratios
In fiscal 2025, Bausch & Lomb Corp had return on equity of -5.6%, an operating margin of 2.2%, debt equal to 79.2% of equity and a current ratio of 1.55. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|
| Operating margin | 7.6% | 8.7% | 5.5% | 3.1% | 3.4% | 2.2% | 7.1% |
| Net margin | −0.5% | 4.8% | 0.2% | −6.3% | −6.6% | −7.1% | −2.0% |
| Free-cash-flow margin | 7.9% | 18.1% | 4.5% | −4.8% | −1.2% | −1.3% | 4.7% |
| Return on equity | −0.2% | 1.9% | 0.1% | −3.7% | −4.8% | −5.6% | −1.7% |
| Return on assets | — | 1.7% | 0.1% | −2.1% | −2.4% | −2.6% | −0.8% |
| Asset turnover | — | 0.35 | 0.34 | 0.34 | 0.36 | 0.37 | 0.39 |
| Current ratio | — | 1.49 | 1.65 | 1.74 | 1.60 | 1.55 | 1.56 |
| Debt to equity | 0.0% | 0.0% | 35.4% | 67.7% | 74.8% | 79.2% | 78.7% |
| Interest cover (operating income ÷ interest) | — | — | 1.4x | 0.5x | 0.4x | 0.3x | 1.0x |
| Effective tax rate | — | 39.3% | 79.5% | — | — | — | — |
| R&D as % of revenue | 7.4% | 7.2% | 8.1% | 7.8% | 7.2% | 7.3% | 7.4% |
| SG&A as % of revenue | 36.7% | 36.9% | 39.2% | 41.9% | 43.5% | 43.8% | 41.6% |
| Capital spending as % of revenue | 7.4% | 5.1% | 4.6% | 4.4% | 6.1% | 6.8% | 5.6% |
| Free cash flow ÷ net income | — | 373.6% | >999% | — | — | — | — |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | 6.8% | −7.3% | −0.9% | 7.4% | 8.0% | 2.7% | 6.0% | 11.3% |
| Net margin | −0.2% | −18.6% | −4.9% | −2.2% | −4.1% | −5.7% | −1.0% | 2.3% |
| Free-cash-flow margin | −5.5% | −11.9% | −4.2% | 4.9% | 4.3% | −5.5% | 5.9% | 12.9% |
| Current ratio | 1.60 | 1.56 | 1.55 | 1.51 | 1.55 | 1.53 | 1.55 | 1.56 |
| Debt to equity | 73.9% | 75.9% | 77.0% | 77.0% | 78.3% | 79.0% | 79.6% | 77.9% |
| R&D as % of revenue | 7.3% | 7.6% | 7.5% | 7.4% | 6.7% | 8.1% | 8.2% | 6.6% |
| SG&A as % of revenue | 41.6% | 49.5% | 45.3% | 41.2% | 40.1% | 43.7% | 42.2% | 40.4% |
Financial health
- Short-term assets cover short-term liabilities $3.1bn of assets due within a year against $2.0bn of liabilities due within a year.
- Short-term assets cover long-term liabilities $3.1bn short-term assets against $5.5bn of longer-dated liabilities.
- More cash than debt $513m of cash against $5.0bn of debt.
- Debt below 40% of shareholders' equity Debt is 78% of equity.
- Debt burden no higher than five years ago Debt to equity moved from 0% to 78% over five years.
- A year's operating cash flow covers at least 20% of debt $554m of operating cash flow against $5.0bn of debt.
- Operating profit covers interest at least five times over Operating income of $383m against $383m of interest.
Moat
Weak moat
How hard Bausch & Lomb's competitive advantage looks for rivals to wear away, judged from 5 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Net income has been a median -1.6% of total assets over 5 years.
- Durability 8 / 20
Operating margin has been a median 3.3%; its worst year was 1.8%.
- Cash conversion 4 / 20
Free cash flow was positive in 2 of 5 years, at a median -0.5% of revenue.
AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.
Compare with peers
- ResMed| statistics
- Dexcom statistics
- Steris statistics
- Idexx Laboratories statistics
- Edwards Lifesciences statistics
Head to head: BLCO vs RMDBLCO vs DXCMBLCO vs STEBLCO vs IDXX
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies